LatestJournalism Under Pressure: Puerto Rican Reporters' Experience Covering Tragedy
Cannabis

Telemedicine and Medical Cannabis: Consultations Surge in Argentina

Redacción
Telemedicine and Medical Cannabis: Consultations Surge in Argentina
AnxietyDepressionChronic PainEpilepsyInsomnia
Summary

Argentina's Clinicann, a telemedicine clinic specializing in medical cannabis, reports treating over 20,000 patients nationwide as demand for therapeutic cannabis access continues to rise. The clinic's expansion reflects years of regulatory delays and litigation surrounding REPROCANN, Argentina's registry for legal therapeutic cannabis cultivation. Private telemedicine services have increasingly filled gaps left by administrative uncertainty in the public healthcare system. This trend highlights how digital health platforms are becoming essential access points for patients seeking cannabis-based treatments in regions with complex regulatory frameworks. The development demonstrates growing patient demand for convenient, professional medical guidance on cannabis therapeutics.

Originally published on

Revista Cáñamo

By Redacción

Read full article(opens in new tab)

Fetched: September 10, 2026 at 10:02 AM

Related News

More news you might be interested in

View all
Got Purps? Understanding Cannabis Effects Through Flavonoids
Cannabis
AnxietyDepression

Got Purps? Understanding Cannabis Effects Through Flavonoids

Flavonoids—the molecules responsible for cannabis flower's vibrant colors and distinctive flavors—are emerging as key compounds in understanding how cannabis produces its therapeutic effects. Beyond their aesthetic role, these polyphenolic compounds interact with cannabinoids like THC and CBD to modulate the plant's pharmacological profile and user experience. Researchers are increasingly focused on how flavonoids contribute to the entourage effect, where multiple plant compounds work synergistically to enhance medicinal benefits for conditions ranging from anxiety to chronic pain. This deeper understanding of flavonoids could revolutionize strain selection and cannabis medicine customization for patients seeking targeted symptom relief.

11 hours ago
Cannabis Now
Federal Hemp Ban Could Force 68.1% of U.S. Hemp Businesses to Close
Cannabis

Federal Hemp Ban Could Force 68.1% of U.S. Hemp Businesses to Close

A Whitney Economics report indicates that a federal ban on intoxicating hemp products would force approximately 68.1% of U.S. hemp-related businesses to close. The ban, originally scheduled for November, was delayed one month in August through an amendment to federal funding legislation. This regulatory action could significantly impact the availability and accessibility of hemp-derived products, including those with potential therapeutic applications. The analysis highlights the substantial economic consequences for the hemp industry and implications for consumers who rely on these products.

13 hours ago
Ganjapreneur
New Mexico Cannabis Tracking System Transition Causes Business Disruptions and Financial Losses
Cannabis

New Mexico Cannabis Tracking System Transition Causes Business Disruptions and Financial Losses

New Mexico's transition to the New Mexico Seed to Sale (NMS2S) tracking system launched September 1 has created operational challenges for cannabis retailers unable to sell products, resulting in significant financial losses. The system replacement, which transitioned from the legacy BioTrack platform that went offline September 7, has left businesses struggling with technical issues during the changeover. This disruption affects the medical cannabis supply chain, potentially impacting patients who depend on consistent access to cannabis for therapeutic purposes. Industry stakeholders report steep losses as the new system stabilizes. The transition highlights the importance of coordinated regulatory technology implementations to minimize patient access disruptions.

13 hours ago
Ganjapreneur
Cannabis Analytics Firm Headset Settles $1M COVID-19 Relief Loan Fraud Claim
Cannabis

Cannabis Analytics Firm Headset Settles $1M COVID-19 Relief Loan Fraud Claim

Cannabis analytics firm Headset Inc. has agreed to pay $1,012,876 to settle allegations that it improperly received a federal Paycheck Protection Program (PPP) loan intended for small businesses during the COVID-19 pandemic. The company was deemed ineligible for the SBA relief funding in 2021. This settlement reflects ongoing enforcement actions against businesses that misused pandemic relief resources. The case highlights regulatory scrutiny within the cannabis industry during government financial assistance programs.

13 hours ago
Ganjapreneur